The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers.

ABSTRACT:

Purpose

Concomitant treatment with the glucose-lowering drug metformin and the platelet aggregation inhibitor dipyridamole often occurs in patients with type 2 diabetes mellitus who have suffered a cerebrovascular event. The gastrointestinal uptake of metformin is mediated by the human equilibrative nucleoside transporter 4 (ENT4), which is inhibited by dipyridamole in preclinical studies. We hypothesized that dipyridamole lowers the plasma exposure to metformin.

Methods

Eighteen healthy volunteers (mean age 23 years; 9 male) were randomized in an open-label crossover study. Subjects were allocated to treatment with metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily or to metformin alone for 4 days. After a washout period of 10 days

SUBMITTER: El Messaoudi S 

PROVIDER: S-EPMC4869751 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature